Adult Dosing

Maintenance treatment of patients with Wilson’s disease

• 50 mg PO zinc tid

Pediatric Dosing

• Safety and efficacy in pediatric patients have not been established

[Outline]

• Adult Dosing
• Pediatric Dosing

• Maintenance treatment of patients with Wilson’s disease who have been initially treated with a chelating agent

• Hypersensitivity to any of the ingredients of the product

• N/A

Renal Dose Adjustment

• Renal impairment: Dose adjustments not defined

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustments not defined

• Therapy is not recommended for the initial therapy of symptomatic patients because of the delay required for zinc-induced increase in enterocytic metallothionein and blockade of copper uptake
• Symptomatic patients should be treated initially, using chelating agents
• During initial therapy, neurological deterioration may occur as stores of copper are mobilized
• Once initial therapy has been completed, and the patient is clinically stable, maintenance treatment with zinc acetate can be considered
• Patients should be monitored primarily by assessment of existing signs and symptoms of Wilson’s disease and 24-hour urine copper
• Neuropsychiatric evaluations including speech as well as liver function tests including bilirubin and aminotransferases, should be done as appropriate
• The clinician should be aware that urinary copper levels are usually increased with chelation therapy such as penicillamine or trientine

Pregnancy Category:A

Breastfeeding: Zinc does appear in breast milk and zinc-induced copper deficiency in the nursing baby may occur. Therefore, it is recommended that women on zinc therapy not nurse their babies.

• GI: Gastric irritation
• LAB TESTS: Elevations of serum alkaline phosphatase, amylase and lipase

• Chelating agent; blocks the intestinal absorption of copper from the diet and the reabsorption of endogenously secreted copper such as that from the saliva, gastric juice and bile
• Metabolism: Unknown
• Excretion: Urinary
• Half-life: Unknown

US Trade Name(s)

• Galzin

US Availability

Galzin

• CAPS: 25, 50 mg

Canadian Trade Name(s)

• N/A

Canadian Availability

• N/A

UK Trade Name(s)

• Wilzin

UK Availability

Wilzin

• CAPS: 25 mg

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

[Outline]

Toxicology

Antidote

Drug Name: Galzin 25 MG Oral Capsule

Ingredient(s): Zinc Acetate

Imprint: 93-215

Color(s): Blue

Shape: Capsule

Size (mm): 19.00

Score: 1

Inactive Ingredient(s): corn starch / magnesium stearate / titanium dioxide / fd&c blue #1

Drug Label Author:
Teva Neuroscience, Inc.

DEA Schedule:
Non-Scheduled

Drug Name: Galzin 50 MG Oral Capsule

Ingredient(s): Zinc Acetate

Imprint: 93-208

Color(s): Orange

Shape: Capsule

Size (mm): 19.00

Score: 1

Inactive Ingredient(s): corn starch / magnesium stearate / titanium dioxide / methylparaben / propylparaben / fd&c red #40 / d&c red #28 / d&c yellow#10

Drug Label Author:
Teva Neuroscience, Inc.

DEA Schedule:
Non-Scheduled